Related Experiment Video
Updated: Aug 7, 2026
07:30
A Simple Approach to Induce Experimental Autoimmune Neuritis in C57BL/6 Mice for Functional and Neuropathological Assessments
Published on: November 9, 2017
[Churg-Strauss syndrome complicated by polyneuropathy]
Csaba Ruzics1, András Folyovich, Agnes Fehér
1Fovárosi Onkormányzat Szent János Kórház, Neurológiai Osztály.
Orvosi Hetilap
|June 21, 2006
Summary
Churg-Strauss syndrome can manifest as subacute axonal polyneuropathy, an early sign of systemic disease. Early diagnosis and immunosuppressive therapy are crucial for remission in this rare condition.
Area of Science:
- Neurology
- Immunology
- Systemic Diseases
Background:
- Polyneuropathy often arises secondary to systemic diseases, with chronic forms appearing years after initial diagnosis.
- Acute-subacute polyneuropathy can be the initial clinical presentation of an underlying systemic disease, even before its characteristic symptoms emerge.
Observation:
- The case study highlights Churg-Strauss syndrome presenting with subacute axonal polyneuropathy and characteristic eosinophilia.
- Diagnosis of polyneuropathy relies on clinical evaluation, electrophysiologic studies, cerebrospinal fluid analysis, and peripheral nerve biopsy.
Findings:
- Churg-Strauss syndrome, though rare, is an important consideration in cases of unexplained polyneuropathy with eosinophilia.
- The presented case underscores the potential for this syndrome to manifest initially as a neurological disorder.
Implications:
- Early recognition of Churg-Strauss syndrome is critical for initiating timely immunosuppressive therapy.
- Prompt treatment can lead to remission and improved patient outcomes, emphasizing the link between systemic vasculitis and neurological complications.
Related Concept Videos
01:22Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
01:19Cushing Syndrome II: Pathophysiology
Cortisol production is normally governed by the hypothalamic–pituitary–adrenal (HPA) axis, which maintains hormonal balance through tightly regulated feedback mechanisms. Disruption of this regulatory system is central to the development of Cushing syndrome, whether the excess cortisol originates from external medications or internal pathology. Persistent cortisol elevation alters metabolism, immune function, and endocrine signaling, producing the characteristic clinical features of the...
01:21Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
01:22Diabetic Neuropathy
DefinitionDiabetic neuropathy is nerve damage caused by long-standing diabetes mellitus. It results directly from prolonged high blood sugar levels.PathophysiologyThe pathophysiology of diabetic neuropathy involves both metabolic and vascular disturbances triggered by chronic hyperglycemia.Metabolic injury: Elevated glucose levels activate the polyol pathway within nerve cells, leading to the accumulation of sorbitol and fructose. This increases oxidative stress, disrupts normal nerve...
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...